SPOTLIGHT -
Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial
Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer
Introduction of the Debate Between Jets v. Giants
An outline of the debate, the speakers, and the basic guidelines to support the program.
Achieving Value in Cancer Care
This video explores the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level while maintaining optimal care for cancer patients.
